Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shire On Course For 2017 Launch Of 'Adderall Beads' For Adult ADHD

This article was originally published in Scrip

Executive Summary

Shire's positive topline data from a pediatric Phase III trial of SHP465 (triple-bead mixed amphetamine salts) addresses the US FDA requirements for a class 2 resubmission for the product's NDA, said the company. The product is slated for US launch in 2017.

Advertisement

Related Content

Goal Finally In Sight For Shire's 'Adderall Beads' Extension Strategy

Topics

Advertisement
UsernamePublicRestriction

Register

SC064919

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel